Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating expenses:
Research and development	$ 1,743,494	$ 1,169,810	$ 4,961,720	$ 4,386,491
General and administrative	1,290,371	1,589,621	3,559,551	4,748,090
Goodwill impairment		4,186,050		4,186,050
Depreciation	18,178	26,723	70,840	81,450
Loss from operations	3,052,043	6,972,204	8,592,111	13,402,081
Other income:
Interest income	(21,991)	(37,981)	(59,596)	(120,784)
Loss from operations before income tax benefit	(3,030,052)	(6,934,223)	(8,532,515)	(13,281,297)
Income tax benefit	(225,960)	(214,493)	(485,216)	(482,425)
Net loss	(2,804,092)	(6,719,730)	(8,047,299)	(12,798,872)
Series A cumulative preferred dividends				(85,993)
Deemed dividend related to the make-whole provision for the conversion of Series A convertible preferred stock into common stock				(8,167,895)
Net loss attributable to common stockholders	$ (2,804,092)	$ (6,719,730)	$ (8,047,299)	$ (21,052,760)
Per share information:
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (0.60)	$ (1.99)	$ (2.01)	$ (6.61)
Weighted average shares outstanding, basic and diluted (in dollars per share)	$ 4,693,290	$ 3,371,468	$ 4,005,919	$ 3,185,865